Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Northwest Biotherapeutics ( (NWBO) ) has shared an update.
Northwest Biotherapeutics has reached a settlement agreement on October 9, 2025, with Lead Plaintiff F. Glenn Schaeffer regarding litigation over option awards made in 2020 to the company’s management and directors. The settlement involves the cancellation of 17% of the challenged options and a $2.25 million payment from the company’s insurers. This agreement concludes a year-long negotiation and mediation process, resolving claims from an amended complaint filed on October 14, 2025. The settlement is subject to court approval, and the company’s insurers will separately cover any attorney fees awarded.
More about Northwest Biotherapeutics
Average Trading Volume: 3,083,404
Technical Sentiment Signal: Strong Sell
Current Market Cap: $369.8M
See more data about NWBO stock on TipRanks’ Stock Analysis page.